George L Morris1, David Gloss, Jeffrey Buchhalter, Kenneth J Mack, Katherine Nickels, Cynthia Harden. 1. From the Aurora Epilepsy Center (G.L.M.), St. Luke's Medical Center, Milwaukee, WI; Barrow Neurologic Institute (D.G.), Phoenix, AZ; University of Calgary (J.B.), Canada; Mayo Clinic (K.J.M., K.N.), Rochester, MN; and Hofstra University North Shore-Long Island Jewish Medical College (C.H.), Great Neck, NY.
Abstract
OBJECTIVE: To evaluate the evidence since the 1999 assessment regarding efficacy and safety of vagus nerve stimulation (VNS) for epilepsy, currently approved as adjunctive therapy for partial-onset seizures in patients >12 years. METHODS: We reviewed the literature and identified relevant published studies. We classified these studies according to the American Academy of Neurology evidence-based methodology. RESULTS: VNS is associated with a >50% seizure reduction in 55% (95% confidence interval [CI] 50%-59%) of 470 children with partial or generalized epilepsy (13 Class III studies). VNS is associated with a >50% seizure reduction in 55% (95% CI 46%-64%) of 113 patients with Lennox-Gastaut syndrome (LGS) (4 Class III studies). VNS is associated with an increase in ≥ 50% seizure frequency reduction rates of ≈ 7% from 1 to 5 years postimplantation (2 Class III studies). VNS is associated with a significant improvement in standard mood scales in 31 adults with epilepsy (2 Class III studies). Infection risk at the VNS implantation site in children is increased relative to that in adults (odds ratio 3.4, 95% CI 1.0-11.2). VNS is possibly effective for seizures (both partial and generalized) in children, for LGS-associated seizures, and for mood problems in adults with epilepsy. VNS may have improved efficacy over time. RECOMMENDATIONS: VNS may be considered for seizures in children, for LGS-associated seizures, and for improving mood in adults with epilepsy (Level C). VNS may be considered to have improved efficacy over time (Level C). Children should be carefully monitored for site infection after VNS implantation.
OBJECTIVE: To evaluate the evidence since the 1999 assessment regarding efficacy and safety of vagus nerve stimulation (VNS) for epilepsy, currently approved as adjunctive therapy for partial-onset seizures in patients >12 years. METHODS: We reviewed the literature and identified relevant published studies. We classified these studies according to the American Academy of Neurology evidence-based methodology. RESULTS: VNS is associated with a >50% seizure reduction in 55% (95% confidence interval [CI] 50%-59%) of 470 children with partial or generalized epilepsy (13 Class III studies). VNS is associated with a >50% seizure reduction in 55% (95% CI 46%-64%) of 113 patients with Lennox-Gastaut syndrome (LGS) (4 Class III studies). VNS is associated with an increase in ≥ 50% seizure frequency reduction rates of ≈ 7% from 1 to 5 years postimplantation (2 Class III studies). VNS is associated with a significant improvement in standard mood scales in 31 adults with epilepsy (2 Class III studies). Infection risk at the VNS implantation site in children is increased relative to that in adults (odds ratio 3.4, 95% CI 1.0-11.2). VNS is possibly effective for seizures (both partial and generalized) in children, for LGS-associated seizures, and for mood problems in adults with epilepsy. VNS may have improved efficacy over time. RECOMMENDATIONS: VNS may be considered for seizures in children, for LGS-associated seizures, and for improving mood in adults with epilepsy (Level C). VNS may be considered to have improved efficacy over time (Level C). Children should be carefully monitored for site infection after VNS implantation.
Authors: Imran I Ali; Noor A Pirzada; Yousuf Kanjwal; Braxton Wannamaker; Azedine Medhkour; Michael T Koltz; Bradley V Vaughn Journal: Epilepsy Behav Date: 2004-10 Impact factor: 2.937
Authors: Vivek Nagaraj; Steven T Lee; Esther Krook-Magnuson; Ivan Soltesz; Pascal Benquet; Pedro P Irazoqui; Theoden I Netoff Journal: J Clin Neurophysiol Date: 2015-06 Impact factor: 2.177
Authors: Winthrop F Gillis; Charles A Lissandrello; Jun Shen; Ben W Pearre; Alket Mertiri; Felix Deku; Stuart Cogan; Bradley J Holinski; Daniel J Chew; Alice E White; Timothy M Otchy; Timothy J Gardner Journal: J Neural Eng Date: 2018-02 Impact factor: 5.379